Leucine-Rich α2-Glycoprotein Is a Novel Biomarker of Neurodegenerative Disease in Human Cerebrospinal Fluid and Causes Neurodegeneration in Mouse Cerebral Cortex

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Miyajima, Masakazu ^a   Nakajima, Madoka ^a   Motoi, Yumiko ^a   Moriya, Masao ^a   Sugano, Hidenori ^a   Ogino, Ikuko ^a   Nakamura, Eri ^a   Tada, Norihiro ^a   Kunichika, Miyuki ^a   Arai, Hajime ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLYCOPROTEIN; LEUCINE RICH ALPHA2 GLYCOPROTEIN; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; BRAIN TISSUE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; EARLY DIAGNOSIS; FEMALE; GERIATRIC PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; NORMOTENSIVE HYDROCEPHALUS; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION; TRANSGENIC MOUSE;

AGED; AGING; ANIMALS; AREA UNDER CURVE; AUTOPSY; BIOLOGICAL MARKERS; BRAIN; CELL LINE; CEREBRAL CORTEX; DEMOGRAPHY; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; PROTEIN BINDING;

EID: 84884226154     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074453     Document Type: Article

References (47)

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421. doi:10.1016/S0197-4580(00)00124-X. PubMed: 10858586.
2. McGeer PL, Schulzer M, McGeer EG, (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 47: 425-432. doi:10.1212/WNL.47.2.425. PubMed: 8757015.
3. Heneka MT, O'Banion MK, (2007) Inflammatory processes in Alzheimer's disease. J Neuroimmunol 184: 69-91. doi:10.1016/j.jneuroim.2006.11.017. PubMed: 17222916.
4. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, et al. (2005) Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 58: 963-967. doi:10.1002/ana.20682. PubMed: 16240369.
5. McGeer PL, McGeer EG, (2007) NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 28: 639-647. doi:10.1016/j.neurobiolaging.2006.03.013. PubMed: 16697488.
6. Vlad SC, Miller DR, Kowall NW, Felson DT, (2008) Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70: 1672-1677. doi:10.1212/01.wnl.0000311269.57716.63. PubMed: 18458226.
7. Lim GP, Yang F, Chu T, Chen P, Beech W, et al. (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20: 5709-5714. PubMed: 10908610.
8. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, et al. (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23: 7504-7509. PubMed: 12930788.
9. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, et al. (2005) Acute treatment with PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta 1-42 levels in APPV717I transgenic mice. Brain 128: 1442-1453. doi:10.1093/brain/awh452. PubMed: 15817521.
10. Berchtold NC, Cribbs DH, Coleman PD, Rogers J, Head E, et al. (2008) Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Sci USA 105: 15605-15610. PubMed: 18832152.
11. Haupt H, Baudner S, (1977) [Isolation and characterization of an unknown, leucine-rich 3.1-S-alpha2-glycoprotein from human serum (author's transl)]. [Article in German]. Hoppe Seylers Z Physiol Chem 358: 639-646. doi:10.1515/bchm2.1977.358.1.639. PubMed: 69600.
12. Matsushima N, Tanaka T, Enkhbayar T, Mikami T, Taga M, et al. (2007) Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate toll-like receptors. BMC Genomics 8: 124. doi:10.1186/1471-2164-8-124. PubMed: 17517123.
13. Kobe B, Kajava AV, (2001) The leucine-rich repeat as a protein recognition motif. Curr Opin Struct Biol 11: 725-732. doi:10.1016/S0959-440X(01)00266-4. PubMed: 11751054.
14. Shirai R, Hirano F, Ohkura N, Ikeda K, Inoue S, (2009) Up-regulation of the expression of leucine-rich alpha(2)-glycoprotein in hepatocytes by the mediators of acute-phase response. Biochem Biophys Res Commun 382: 776-779. doi:10.1016/j.bbrc.2009.03.104. PubMed: 19324010.
15. Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM, (2013) Clinical utility and analytical changes in measurement of cerebrospinal fluid amyloid-β1-42 and τproteins as Alzheimer disease biomarkers. Clin Chem 59: 903-916. doi:10.1373/clinchem.2013.202937. PubMed: 23519967.
16. Koivisto AM, Alafuzoff I, Savolainen S, Sutela A, Rummukainen J, et al. (2013) Poor cognitive outcome in shunt-responsive idiopathic normal pressure hydrocephalus. Neurosurgery 72: 1-8. doi:10.1227/NEU.0b013e31827db647. PubMed: 23037817.
17. Nakajima M, Miyajima M, Ogino I, Watanaba M, Miyata H, et al. (2011) Leucine-rich α-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus. Acta Neurochir (Wien) 153: 1339-1346. doi:10.1007/s00701-011-0963-z.
18. Miyajima M, Nakajima M, Ogino I, Miyata H, Motoi Y, et al. (2013) Soluble amyloid precursor protein α in the cerebrospinal fluid as a diagnostic and prognostic biomarker for idiopathic normal pressure hydrocephalus. Eur J Neurol 20: 236-242. doi:10.1111/j.1468-1331.2012.03781.x. PubMed: 22672777.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINDS-ADRDA Work Group under the auspices of Department of health and Human Service Task Force on Alzheimer's disease. Neurology 34: 939-944. doi:10.1212/WNL.34.7.939. PubMed: 6610841.
20. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, et al. (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele: Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47: 1-9.
21. Niwa H, Yamamura K, Miyazaki J, (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199. doi:10.1016/0378-1119(91)90434-D. PubMed: 1660837.
22. Zhuo L, Theis M, Alvarez-Maya I, Brenner M, Willecke K, et al. (2001) hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo. Genesis, 31: 85-94. doi:10.1002/gene.10008. PubMed: 11668683.
23. Li X, Miyajima M, Mineki R, Taka H, Murayama K, et al. (2006) Analysis of potential diagnostic biomarker in cerebrospinal fluid of idiopathic normal pressure hydrocephalus by proteomics. Acta Neurochir (Wien) 148: 859-864. doi:10.1007/s00701-006-0787-4.
24. Nakajima M, Miyajima M, Ogino I, Watanabe M, Miyata H, et al. (2012) Brain localization of leucine-rich α2-glycoprotein and its role. Acta Neurochir Suppl 113: 97-101. doi:10.1007/978-3-7091-0923-6_20. PubMed: 22116432.
25. Paisán-Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, et al. (2004) Cloning of the gene containing mutation that cause PARK8-linked Parkinson's disease. Neuron 44: 595-600. doi:10.1016/j.neuron.2004.10.023. PubMed: 15541308.
26. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601-607. doi:10.1016/j.neuron.2004.11.005. PubMed: 15541309.
27. Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, et al. (2005) An LRRK2 mutation as a cause for the parkinsonism in the original Park 8 family. Ann Neurol 57918-921.
28. Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, et al. (2005) A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365: 412-415. doi:10.1016/S0140-6736(05)70236-1. PubMed: 15680456.
29. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, et al. (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365: 415-416. doi:10.1016/S0140-6736(05)70237-3. PubMed: 15680457.
30. Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, et al. (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76: 672-680. doi:10.1086/429256. PubMed: 15726496.
31. Nichols WC, Pankratz N, Hernandez D, Paisán-Ruíz C, Jain S, et al. (2005) Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365: 410-412. doi:10.1016/S0140-6736(05)17828-3. PubMed: 15680455.
32. Toft M, Mata IF, Kachergus JM, Ross OA, Farrer MJ, (2005) LRRK2 mutations and Parkinsonism. Lancet 365: 1229-1230. doi:10.1016/S0140-6736(05)74809-1. PubMed: 15811454.
33. Lesage S, Dürr A, Tazir M, Lohmann E, Leutenegger AL, et al. (2006) LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 354: 422-423. doi:10.1056/NEJMc055540. PubMed: 16436781.
34. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, et al. (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40: 955-962. doi:10.1038/ng.175. PubMed: 18587394.
35. Serada S, Fujimoto M, Ogata A, Terabe F, Hirano T, et al. (2010) iTAQ-based proteomic identification of leucine-rich α-2 glycoprotein as a novel inflammatory biomarker in autoimmune disease. Ann Rheum Dis 69: 770-774. doi:10.1136/ard.2009.118919. PubMed: 19854709.
36. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, et al. (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol 106: 518-526. doi:10.1007/s00401-003-0766-2. PubMed: 14513261.
37. Thévenet J, Pescini Gobert R, Hooft van Huijsduijnen R, Wiessner C, Sagot YJ, (2011) Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLOS ONE 6: e21519. doi:10.1371/journal.pone.0021519. PubMed: 21738687.
38. Hakimi M, Selvanantham T, Swinton E, Padmore RF, Tong Y, et al. (2011) Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm 118: 795-808. doi:10.1007/s00702-011-0653-2. PubMed: 21552986.
39. Gardet A, Benita Y, Li C, Sands BE, Ballester I, et al. (2010) LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol 185: 5577-5585. doi:10.4049/jimmunol.1000548. PubMed: 20921534.
40. Mutez E, Larvor L, Leprêtre F, Mouroux V, Hamalek D, et al. (2011) Transcriptional profile of Parkinson' blood mononuclear cells with LRRK2 mutation. Neurobiol Aging 32: 1839-1848. doi:10.1016/j.neurobiolaging.2009.10.016. PubMed: 20096956.
41. Liu Z, Lee J, Krummey S, Lu W, Cai H, et al. (2011) The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol 12: 1063-1070. doi:10.1038/ni.2113. PubMed: 21983832.
42. Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, et al. (2012) LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 32: 1602-1611. doi:10.1523/JNEUROSCI.5601-11.2012. PubMed: 22302802.
43. Serada S, Fujimoto M, Terabe F, Iijima H, Shinzaki S, et al. (2012) Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis 18: 2169-2179. doi:10.1002/ibd.22936. PubMed: 22374925.
44. Linhoff MW, Laurén J, Cassidy RM, Dobie FA, Takahashi H, et al. (2009) An unbiased expression screen for synaptogenic proteins identifies the LRRTM protein family as synaptic organizers. Neuron 61: 734-749. doi:10.1016/j.neuron.2009.01.017. PubMed: 19285470.
45. Siddiqui TJ, Pancaroglu R, Kang Y, Rooyakkers A, Craig AM, (2010) LRRTMs and neuroligins bind neurexins with a differential code to cooperate in glutamate synapse development. J Neurosci 30: 7495-7506. doi:10.1523/JNEUROSCI.0470-10.2010. PubMed: 20519524.
46. Chen YK, Hsueh YP, (2012) Cortactin-binding protein 2 modulates the mobility of cortactin and regulates dendritic spine formation and maintenance. J Neurosci 32: 1043-1055. doi:10.1523/JNEUROSCI.4405-11.2012. PubMed: 22262902.
47. Lantos PL, (2000) Diagnostic criteria for corticobasal degeneration. J Neurol Neurosurg Psychiatry 69: 705-706. doi:10.1136/jnnp.69.5.705a. PubMed: 11184240.